Privacy Policy
This Privacy Policy describes what information we may collect about you; how we use your information;
how we protect it; and what choices you have. Health is a very personal, private subject, and we want you to feel
as comfortable as possible visiting our various Web sites and using their respective services. This Privacy Policy
applies only to websites that directly link to this policy when you click on Privacy Policy in the website footer.
Personally Identifiable Information
United Therapeutics Corporation ("UT") may collect personally identifiable information such as name, address,
telephone number, e‐mail address, or other information only when voluntarily submitted by the visitor
(i.e. on a web form you fill out and submit). UT uses or discloses personally identified information only with the visitor's
consent. UT will comply with any limitations on use communicated when personally identifiable information is collected.
UT will not sell, trade, or rent your personally identifiable information to others. UT may however, share your personally
identifiable information with other UT businesses or affiliates, our agents, contractors or business partners in order that
they may perform services for us.
UT may use your personally identifiable information for the purposes of sending you information about this website,
marketing communications about its products, information about disease states treated with UT’s products, information about
support groups for patients and peer givers, educational opportunities, conferences, and seminars, and similar information.
Non‐Personally Identifiable Information
UT collects non‐personally identifiable information in aggregate form to track data such as the total number of visits to
our web sites, the number of visitors to each page of our web sites, and the domain names of our visitors' Internet service
providers. We use this information, which remains in aggregate form, to understand how our visitors use our web sites so that
we may make them better. We may also share this information with our partners or other outside companies. This information is
gathered primarily through the use of "cookies." You may be able to change the manner in which your browser manages cookies
through your browser’s privacy settings. NO PERSONALLY IDENTIFIABLE INFORMATION IS OBTAINED IN THIS PROCESS.
UT uses third party advertising companies to advertise on our behalf across the Internet. These third parties may collect
anonymous information about your visits to our website, and your interaction with our ads. This is primarily accomplished
through technologies including cookies and Action Tags (commonly referred to as a Web Beacons or GIF tags), which are placed
on various places within our website. NO PERSONALLY IDENTIFIABLE INFORMATION IS DISCLOSED IN THIS PROCESS.
Security
UT uses technical and organizational security precautions to protect your data from manipulation, loss, destruction
or access by unauthorized persons. Any personal data that is provided to UT by you will be secured in transit to prevent its
possible misuse by third parties. Our security procedures are revised from time to time based on new technological developments.
Voluntary Disclosures
Any communications or material that you transmit to, or post on, the site by electronic mail or otherwise, including any data,
questions, comments, suggestions, or the like, is, and will be treated as, non‐confidential and non‐proprietary information,
and UT shall have no obligation of any kind with respect to such information except as otherwise stated in this Privacy Policy.
Links to Other Web Sites
UT web sites may provide links to other web sites as a service to our viewers. These linked web sites are intended to provide
helpful information. However, UT does not endorse and is not responsible for the content of third‐party sites. Nor does UT
have any control over the information you may choose to provide these sites. This Privacy Policy does not apply to linked sites.
Changes to Privacy Policy
Any changes to this Privacy Policy will be communicated promptly on this page. Please check back periodically.
HOW TO CONTACT United Therapeutics.
If you have questions or comments about this Privacy Statement, please contact:
Office of General Counsel
United Therapeutics/United Therapeutics
legal@unither.com
Important Safety Information for ADCIRCA® (tadalafil) tablets
CONTRAINDICATIONS
- Nitrates and Guanylate Cyclase (GC) Stimulators: Do not use ADCIRCA in patients taking medicines
that contain nitrates or guanylate cyclase stimulators (such as riociguat), as the combination could cause a sudden,
unsafe drop in blood pressure. Do not use nitrates within 48 hours of the last dose of ADCIRCA.
- Hypersensitivity Reactions: Patients with a known serious hypersensitivity to tadalafil
should not take ADCIRCA
WARNINGS AND PRECAUTIONS
- Cardiovascular: Patients who experience anginal chest pain after taking ADCIRCA
should seek immediate medical attention
- Hypotension: Phosphodiesterase 5 inhibitors (PDE-5is), including tadalafil, have mild systemic
vasodilatory properties that may result in transient decreases in blood pressure. Before prescribing ADCIRCA, carefully
consider whether patients with underlying cardiovascular disease could be adversely affected by such actions.
- Worsening Pulmonary Vascular Occlusive Disease: Pulmonary vasodilators may significantly worsen the
cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD) and administration of ADCIRCA to these
patients is not recommended
- Vision/Hearing: Patients who experience a sudden loss of vision in one or both eyes, which could
be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), or sudden decrease or loss of hearing after taking
ADCIRCA should seek immediate medical attention
- Prolonged Erection: In rare instances, men taking PDE-5is (including tadalafil) for ED reported
an erection lasting more than four hours. Male patients who experience a prolonged erection should seek immediate medical
attention
SPECIAL POPULATIONS AND POTENTIAL DRUG INTERACTIONS:
- Special Populations (Pregnant or Expecting Pregnancy): Limited data from case series with
tadalafil use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse
maternal or fetal outcomes. Pregnant women with untreated pulmonary arterial hypertension are at risk for heart failure,
stroke, preterm delivery, and maternal and fetal death.
- Special Populations (Renal or Hepatic Impairment): The use of ADCIRCA is not recommended for
patients with severe renal or hepatic impairment. Please see Full Prescribing Information for dosing recommendations for
patients with mild to moderate renal or hepatic impairment
- Potential Drug Interactions: The use of ADCIRCA with alpha blockers, blood pressure medications,
or alcohol may lower blood pressure significantly and may lead to symptomatic hypotension (light-headedness or fainting)
- Potential Drug Interactions: Tadalafil is metabolized predominately by CYP3A in the liver. Use of
ADCIRCA with potent CYP3A inhibitors, such as ketoconazole and itraconazole, should be avoided. For patients on ADCIRCA
therapy that require treatment with ritonavir, ADCIRCA should be discontinued at least 24 hours prior to starting ritonavir.
For patients on ritonavir therapy that require treatment with ADCIRCA, start ADCIRCA at 20 mg once a day. Use of ADCIRCA with
potent inducers of CYP3A, such as rifampin, should be avoided
- Potential Drug Interactions: ADCIRCA contains the same ingredient (tadalafil) as Cialis®, which is
used to treat erectile dysfunction (ED) and the signs and symptoms of benign prostatic hyperplasia (BPH). The safety and
efficacy of combinations of ADCIRCA with Cialis or other PDE-5is have not been studied. Therefore, the use of such combinations
is not recommended
ADVERSE REACTIONS
- Adverse Reactions: The most common adverse event with ADCIRCA is headache (42% ADCIRCA
vs 15% placebo). Other common adverse events (reported by ≥9% of patients on ADCIRCA
and more frequent than placebo by 2%) include myalgia (14% vs 4%), nasopharyngitis
(13% vs 7%), flushing (13% vs 2%), respiratory tract infection (13% vs 6%), extremity
pain (11% vs 2%), nausea (11% vs 6%), back pain (10% vs 6%), dyspepsia (10% vs 2%),
and nasal congestion (9% vs 1%)
ADC.ISI.HCP.SEP2020
For more information about ADCIRCA, please see the Full Prescribing Information and
Patient Information or call 1-800-545-5979.